Literature DB >> 12648024

Pharmacokinetic principles of bacteriophage therapy.

Robert J H Payne1, Vincent A A Jansen.   

Abstract

Use of bacteriophage to control bacterial infections, including antibiotic-resistant infections, shows increasing therapeutic promise. Effective bacteriophage therapy requires awareness of various novel kinetic phenomena not known in conventional drug treatments. Kinetic theory predicts that timing of treatment could be critical, with the strange possibility that inoculations given too early could be less effective or fail completely. Another paradoxical result is that adjuvant use of an antibiotic can sometimes diminish the efficacy of phage therapy. For a simple kinetic model, mathematical formulae predict the values of critical density thresholds and critical time points, given as functions of independently measurable biological parameters. Understanding such formulae is important for interpreting data and guiding experimental design. Tailoring pharmacokinetic models for specific systems needs to become standard practice in future studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648024     DOI: 10.2165/00003088-200342040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance.

Authors:  M Lipsitch; B R Levin
Journal:  Int J Tuberc Lung Dis       Date:  1998-03       Impact factor: 2.373

Review 2.  Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential.

Authors:  P A Barrow; J S Soothill
Journal:  Trends Microbiol       Date:  1997-07       Impact factor: 17.079

3.  Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986.

Authors:  S Slopek; B Weber-Dabrowska; M Dabrowski; A Kucharewicz-Krukowska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1987       Impact factor: 4.291

4.  Immunogenic effect of bacteriophage in patients subjected to phage therapy.

Authors:  A Kucharewicz-Krukowska; S Slopek
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1987       Impact factor: 4.291

Review 5.  Antibiotic resistance in bacteria.

Authors:  F E Berkowitz
Journal:  South Med J       Date:  1995-08       Impact factor: 0.954

6.  Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth.

Authors:  J Cao; Y Sun; T Berglindh; B Mellgård; Z Li; B Mårdh; S Mårdh
Journal:  Biochim Biophys Acta       Date:  2000-03-06

7.  The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages.

Authors:  H W Smith; M B Huggins; K M Shaw
Journal:  J Gen Microbiol       Date:  1987-05

8.  The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium.

Authors:  A Berchieri; M A Lovell; P A Barrow
Journal:  Res Microbiol       Date:  1991-06       Impact factor: 3.992

Review 9.  The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens.

Authors:  F C Tenover; J M Hughes
Journal:  JAMA       Date:  1996 Jan 24-31       Impact factor: 56.272

10.  Bacteriophage treatment of suppurative skin infections.

Authors:  M Cisło; M Dabrowski; B Weber-Dabrowska; A Woytoń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1987       Impact factor: 4.291

View more
  52 in total

1.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

Review 2.  Bacteriophage secondary infection.

Authors:  Stephen T Abedon
Journal:  Virol Sin       Date:  2015-01-13       Impact factor: 4.327

3.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.

Authors:  Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan
Journal:  Pharm Res       Date:  2016-02-29       Impact factor: 4.200

Review 4.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

5.  Phage Therapy: Future Inquiries.

Authors:  Sijia Wu; Elisabeth Zachary; Keenan Wells; Catherine Loc-Carrillo
Journal:  Postdoc J       Date:  2013-06

6.  In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model.

Authors:  J J Bull; G Otto; I J Molineux
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

7.  Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections.

Authors:  Diana D Semler; Amanda D Goudie; Warren H Finlay; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

8.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  A tale of tails: Sialidase is key to success in a model of phage therapy against K1-capsulated Escherichia coli.

Authors:  J J Bull; E R Vimr; I J Molineux
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

10.  Phage Therapy - Everything Old is New Again.

Authors:  Andrew M Kropinski
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.